Takeda Eyes Irish Opportunities Despite Access Issues
Executive Summary
The Japanese drug maker has invested steadily in its operations in Ireland and is looking to expand further.
You may also be interested in...
Delayed Medicines To Hit Irish Market, But Uncertainty Remains For Future
Nine new approved treatments that have faced delays in getting to Irish patients should hit the market this year, says the Health Service Executive. The innovative pharmaceutical industry welcomes the move but is calling for clear political direction on future processes.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.